Semaglutide, also known by its generic name Wegovy, is a glucagon-like peptide-1 (GLP-1) agonist used in conjunction with a reduced-calorie diet and exercise to promote sustainable weight loss. It has demonstrated more potent effects compared to other medications in its class, potentially due to its higher dosage.
By binding to brain receptors that regulate hunger and appetite, Semaglutide alters food preferences and reduces calorie consumption. Its mechanism of action involves delaying stomach emptying and slowing intestinal motility, leading to prolonged satiety. Additionally, GLP-1 agonists stimulate insulin secretion and decrease glucagon release, resulting in lower blood glucose levels.
On average, patients lose up to 15% of their body weight on this program.